Darshan Mehta

Graduate Student
University of Southern California

Papers:

16 Cost effectiveness of adding bevacizumab to first line therapy of patients with advanced ovarian cancer

American Society of Health Economists (ASHEcon)

1100 Vermont Avenue NW Suite 650

Washington, DC 20005

P: (202) 737 6608

F: (202) 496 0134

Copyright © 2017 ASHEcon - All rights reserved.